NICE: how to switch NHS patients from Remicade to a biosimilar
This article was originally published in Scrip
Executive Summary
The National Institute for Health and Care Excellence (NICE) has produced some "practical advice" for NHS staff on how to manage the introduction of the two biosimilar versions of Merck & Co/J&J's Remicade (infliximab) that were launched in the UK in February this year following further patent expiries on the originator.